7th Annual Gulf-Atlantic Veterinary Conference
Immune-mediated hemolytic anemia is a common canine immune-mediated disease. It is characterized by the body’s own immune system destroying red blood cells resulting from a type II hypersensitivity reaction. The disease may be idiopathic (primary) or secondary to infectious, neoplastic and autoimmune disorders. Consensus is lacking for standardized diagnostics and treatments with it being necessary to eliminate possible secondary causes of disease before therapy is initiated. Evidence-based treatment protocols are lacking with the aim of therapy being to attenuate red blood cell destruction with various immunosuppressive therapies. Despite this, morbidity and mortality remain high due to complications arising from the disease itself and the therapy initiated. The mainstay of treatment is immunosuppressive therapy, thromboprophylaxis and supportive care measures to help prevent and treat concurrent conditions. In this lecture, an overview of the disease will be presented as well as new and up-to-date diagnostics and therapies.